RSV infection in prematurely born infants
- PMID: 16738047
- PMCID: PMC2111227
RSV infection in prematurely born infants
Conflict of interest statement
Competing interests: The author has previously questioned the cost effectiveness of palivizumab in relation to its recommended indications.
Comment on
-
Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants.Thorax. 2005 Dec;60(12):1039-44. doi: 10.1136/thx.2004.037853. Epub 2005 Oct 14. Thorax. 2005. PMID: 16227330 Free PMC article.
References
-
- IMpact‐RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high‐risk infants. Pediatrics 1998102531–537. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical